Evidence map›Paper›PMID 33778705›Full record

ArticleRadiology. Imaging cancer2020

Gadolinium-based Contrast Agents Improve Detection of Recurrent Soft-Tissue Sarcoma at MRI.

Behrang Amini, William A Murphy, Tamara Miner Haygood, Rajendra Kumar, Kevin W McEnery, John E Madewell, Bilal M Mujtaba, Wei Wei, Colleen M Costelloe

Abstract read
In one paragraph

Article in Radiology. Imaging cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The Use of Gadolinium in Musculoskeletal MRI-Time to Rethink?The Indian journal of radiology & imaging · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Behrang AminiDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).ORCID 0000-0002-4962-3466
William A MurphyDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).ORCID 0000-0002-7333-2642
Tamara Miner HaygoodDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).ORCID 0000-0002-7610-5939
Rajendra KumarDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).
Kevin W McEneryDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).
John E MadewellDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).
Bilal M MujtabaDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).
Wei WeiDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).
Colleen M CostelloeDepartment of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1475, Houston, TX 77030 (B.A., W.A.M., T.M.H., R.K., K.W.M., J.E.M., B.M.M., C.M.C.); and Department of Biostatistics, Taussig Cancer Institute, Cleveland, Ohio (W.W.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To determine the diagnostic efficacy of gadolinium-based contrast agents for the detection of recurrent soft-tissue sarcoma compared with non-contrast-enhanced conventional MRI sequences. Materials and Methods: A retrospective study of patients with soft-tissue sarcomas who were imaged from January 2009 to December 2014 was performed. MRI studies from 69 patients (mean age, 61 years ± 15 [standard deviation], 45 men) with recurrent soft-tissue sarcoma and 63 age-, sex-, and tumor-matched controls with positive findings (nonrecurrence) were presented to six musculoskeletal radiologists at a tertiary cancer center in three image groupings. Group 1 consisted of precontrast T1-weighted and fat-suppressed T2-weighted images (no contrast agent). Group 2 consisted of precontrast and postcontrast fat-saturated T1-weighted images. Group 3 consisted of precontrast and fat-saturated postcontrast T1- and fat-suppressed T2-weighted images. Images within these three groups contained either recurrent soft-tissue sarcomas or positive postoperative findings (nonsarcoma). The presentation order of the first two image sets was reversed for half the readers. The readers were asked to classify presence of tumor on a five-point scale. The average score from the readers was used as consensus score for each case, and a case was considered positive if the average score was less than 3. Receiver operating characteristic (ROC) analysis was performed using the average score for each image set. Results: Assessment of the group 3 image set resulted in higher sensitivity (74%, 95% confidence interval [CI]: 62%, 83%) than the group 2 image set (64%, 95% CI: 51%, 75%), which was also more sensitive than the assessment of the group 1 images set (49%, 95% CI: 37%, 61%), with Conclusion: Gadolinium-based contrast agents improved diagnostic performance in detection of recurrent soft-tissue sarcoma. Addition of fat-saturated T2-weighted images provided modest improvement in sensitivity.

Indexed as

Contrast MediaSarcomaAgedFemaleGadoliniumHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesSoft Tissue NeoplasmsContrast MediaGadolinium

Identifiers

PMID33778705
PMCPMC7983747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.